Shanghai Universal Biotech Co Ltd

Shanghai Universal Biotech Co Ltd maintains a strong liquidity position, with a current ratio of 8.7, indicating a high ability to meet short-term obligations. However, the company's free cash flow is negative at -79,358,890 CNY, suggesting that capital expenditures are outpacing operating cash flow. The price-to-book ratio of 1.3 and a price-to-tangible-book ratio of 1.3 indicate that the company's market value is slightly above its book value. The company's profitability is modest, with a return on equity (ROE) of 0.49% and a return on assets (ROA) of 0.44%, both below the typical thresholds for pharmaceutical firms. The gross profit margin is 18.01%, and the operating margin is 0.07%, which is significantly lower than the industry median for pharmaceutical companies. The net income of 10,149,050 CNY is relatively small compared to the company's revenue of 1,117,756,370 CNY, indicating limited profitability. The company's revenue is primarily derived from the sale of life science reagents, with a focus on immunological reagents, molecular biology reagents, and cell biology reagents. The geographic exposure is concentrated in China, as the company is based in Shanghai and operates primarily within the domestic market. There is no disclosed information on international revenue distribution, suggesting a high concentration risk. The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The historical revenue growth is not disclosed, but the modest net income and low ROE suggest limited growth potential. The company's capital expenditures of -71,199,910 CNY indicate significant investment in infrastructure or equipment, which could support future growth. The risk assessment indicates a medium liquidity risk, with a negative net cash position after subtracting total debt. The dilution risk is low, and there are no immediate signs of equity dilution. The company's debt-to-equity ratio of 0.01 is very low, indicating minimal leverage and a conservative capital structure. Recent events and filings do not provide specific details on the company's strategic initiatives or financial performance beyond the disclosed financial snapshot. The company's focus on third-party brand products and technical services suggests a reliance on external suppliers and partners, which could introduce supply chain risks.